The Chinese biotech is now conducting a Phase III study on glecirasib and sitneprofatib, which could see it gain approval on ...

A national survey of 157 patients with non-small cell lung cancer found that all groups prioritized extending life, but ...

New NSCLC guideline updates outline expanded perioperative immunotherapy, adjuvant targeted therapy, and consolidation strategies, supported by phase III data and informed by molecular testing.

Silevertinib delivers robust anti-tumor activity as demonstrated by an ORR of 60% and a CNS response rate of 86% in 43 1L NSCLC patients ...

Clinical research presented at the European Society for Medical Oncology Congress 2024 highlights the significant survival benefits of perioperative and neoadjuvant immunotherapy with nivolumab and ...

Neladalkib showed a 31% ORR in TKI-pretreated ALK+ NSCLC patients, with durable responses at 12 and 18 months.

The FDA has granted an accelerated approval to sevabertinib (Hyrnuo) for the treatment of adult patients with previously ...

About 40% of people with non-small cell lung cancer (NSCLC)—a type of cancer that begins in the tissues of your lungs—have metastatic disease at the time of their diagnosis. Metastatic NSCLC refers to ...

ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced two late-breaking oral ...

Over the past two decades, thoracic oncology has undergone a profound transformation, moving from limited chemotherapy ...